November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
The FDA did not approve a testosterone drug because of safety concerns.
December 2014 in “Journal of Biomedical Research” Recombinant thymosin β4 promotes blood vessel growth and reduces muscle damage.
3 citations
,
June 2018 in “Internal Medicine” Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
January 2011 in “Side effects of drugs annual” Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
3 citations
,
January 2018 in “Archives of Disease in Childhood” Switching to generic tacrolimus was safe, effective, and saved money.
1 citations
,
August 2023 in “The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics” Kir6.1 mutations in Cantú syndrome increase channel sensitivity and hyperpolarization, while SUR2B mutations do not.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
40 citations
,
October 2009 in “Journal of Biomedical Nanotechnology” Pyrene excimer nucleic acid probes are promising for detecting biomolecules accurately with potential for biological research and drug screening.
39 citations
,
April 2019 in “The journal of immunology/The Journal of immunology” Malt1 protease is essential for regulatory T cell function and could be targeted to boost antitumor immunity.
November 2025 in “Archives of Dermatological Research” Using a higher concentration of triamcinolone acetonide leads to faster hair regrowth in scalp patchy alopecia areata.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
13 citations
,
March 2002 in “Pediatric Dermatology” A child was initially wrongly diagnosed with a fungal scalp infection but actually had a non-scarring hair loss condition called Temporal Triangular Alopecia.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
January 1985 in “Clinical research” Topical alpha-terthienyl with UVA may safely treat psoriasis without cancer risk.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.